Research programme: GPCR-uPAR - Science Park Raf/Heidelberg Pharma AG

Drug Profile

Research programme: GPCR-uPAR - Science Park Raf/Heidelberg Pharma AG

Alternative Names: Research programme: anticancer therapeutics - Science Park Raf/Heidelberg Pharma; Signal transduction pathway inhibitors - Science Park Raf/Heidelberg Pharma

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Science Park Raf
  • Developer Science Park Raf; Wilex
  • Class Antibodies
  • Mechanism of Action G protein-coupled receptor antagonists; Signal transduction pathway inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Feb 2005 Preclinical trials in Cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top